The Hematology ASH Education Program 2020 provides review articles from the Education Program at the 2020 ASH Annual Meeting. In this publication, each chapter relates to a different session presented at the meeting, spanning the spectrum from basic discovery and disease pathogenesis to the clinical application at the bedside.
Hematology 2020 is now freely available to be read by the public at large. The content no longer maintains an embargo period.
This activity is supported by educational grants from Amgen, AstraZeneca, Bristol Myers Squibb, Incyte Corporation, Jazz Pharmaceuticals, and Novartis Pharmaceuticals.
Cover Image: Neutrophils
Source: Animated Healthcare Ltd/Science Photo Library
- Define the components of an effective T-cell–mediated immune response
- Identify deficiencies in the immune response in lymphoma
- Describe strategies to overcome the immune deficiencies including the use of immune checkpoint blockade, bispecific molecules, CD47/signal-regulatory protein α blockade, and chimeric antigen receptor T cells
- Understand how venetoclax inhibits BCL2 to trigger apoptosis of CLL and AML cells and other blood cancers and how resistance can develop
- Understand the results of pivotal trials in CLL and AML and how tailored venetoclax combinations may prove effective in other diseases
- Discuss the impact of the presence of comorbidities with CML on patients’ long-term outcomes and the selection of TKIs
- Review the management of patients with CML and comorbidities and suggest recommendations to address the most common needs